Zhu Jianbing, Yao Kang, Wang Qian, Guo Junjie, Shi Hongtao, Ma Leilei, Liu Haibo, Gao Wei, Zou Yunzeng, Ge Junbo
Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Cell Physiol Biochem. 2016;40(6):1591-1602. doi: 10.1159/000453209. Epub 2016 Dec 21.
In this study, we tested the hypothesis that miR-181a levels increase during acute myocardial infarction. We investigated circulating miR-181a as a potential novel biomarker for early diagnosis of acute myocardial infarction (AMI).
From June 2014 to June 2016, 120 consecutive eligible patients with AMI (n = 60) or unstable angina (UA; n = 60) and 60 control subjects were enrolled. Plasma miR-181a levels were determined by quantitative reverse transcriptase-polymerase chain reaction.
Circulating miR-181a expression levels detected immediately after admission were higher in the AMI group than in the UA and control groups. Relative miR-181a levels in AMI patients were positively correlated with the concentrations of the creatine kinase-MB fraction and cardiac troponin I. Correlation analysis showed that plasma miR-181a was positively correlated with coronary Gensini score (r = 0.573, P < 0.05) and negatively correlated with left ventricular ejection fraction (r = -0.489, P < 0.05). Receiver operating characteristic curve analyses showed that plasma miR-181a was of significant diagnostic value for AMI (AUC, 0.834; 95% CI, 0.756-0.912, P < 0.05).
Circulating miR-181a levels in patients with AMI were significantly changed in a time-dependent manner, indicating the value of plasma miR-181a as a novel biomarker for diagnosing AMI.
在本研究中，我们检验了急性心肌梗死期间miR-181a水平会升高这一假设。我们研究了循环miR-181a作为急性心肌梗死（AMI）早期诊断的一种潜在新型生物标志物。
2014年6月至2016年6月，连续纳入120例符合条件的AMI患者（n = 60）或不稳定型心绞痛（UA；n = 60）患者以及60名对照者。通过定量逆转录-聚合酶链反应测定血浆miR-181a水平。
AMI组入院后即刻检测到的循环miR-181a表达水平高于UA组和对照组。AMI患者中miR-181a相对水平与肌酸激酶-MB同工酶和心肌肌钙蛋白I的浓度呈正相关。相关性分析显示，血浆miR-181a与冠状动脉Gensini评分呈正相关（r = 0.573，P < 0.05），与左心室射血分数呈负相关（r = -0.489，P < 0.05）。受试者工作特征曲线分析显示，血浆miR-181a对AMI具有显著诊断价值（AUC，0.834；95% CI，0.756 - 0.912，P < 0.05）。
AMI患者的循环miR-181a水平随时间显著变化，表明血浆miR-181a作为诊断AMI的新型生物标志物具有价值。
